Wockhardt Limited announced its Q2 FY25 financial results, reflecting moderate revenue growth alongside persistent losses. Here are the key highlights of Wockhardt’s performance for the quarter:
Revenue from Operations:
- The company reported revenue from operations at ₹809 crore for Q2 FY25, showing a YoY increase of 7.4% compared to ₹753 crore in Q2 FY24.
- On a sequential basis, revenue increased by 9.5% from ₹739 crore in Q1 FY25.
Net Loss:
- Wockhardt reported a net loss of ₹22 crore in Q2 FY25, an improvement over the net loss of ₹77 crore in Q2 FY24.
- However, on a QoQ basis, the net loss widened slightly from ₹14 crore in Q1 FY25.
Analysis and Outlook:
Wockhardt’s revenue growth reflects the company’s efforts to strengthen its operational performance. However, the consistent net losses indicate challenges in achieving profitability, impacted by factors such as increased costs and financial expenses. The company’s focus on improving cost efficiencies and managing expenses will be crucial as it navigates the competitive pharmaceutical landscape.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
